To identify the principal neutralization determinant (PND) of simian immunodeficiency virus (SIV), antisera were generated using recombinant gpllO [ 
gpllO and gpl4O, large envelope fragments, and synthetic peptides (including peptides analogous to the iHV-1 PND) elicited very low or undetectable neutralizing antibody titers and did not inhibit neutralizing antibody in infected macaque sera. Enzymatically deglycosylated gpllO efficientiy absorbed neutralizing antibodies from macaque sera, showing that neutrling antibodies primarily bind the protein backbone. A 45-kDa protease digest product, mapping to the carboxylterinal third of gpllO, also completely absorbed neutrzing antibodies from infected macaque sera. These results show that the PND(s) of this SnY isolate depends on the native conformation and that linear peptides corresponding to the V3 loop of SnY envelope, in contrast to that of HIV-1, do not elicit neutrlzing antibody. This may affect the usefulness of SIV, for evalnatIngHIV-1 envelope vaccine approaches that rely on eliciftng neutaliing antibody.
bind the PND (16) . The PND of HIV-1 can therefore be mimicked with synthetic peptides and is not dependent on the tertiary structure ofgpl20. Recent chimpanzee immunization and challenge experiments have shown a correlation between the presence of PND-binding neutralizing antibody and protection from infection (17) (18) (19) , and passive immunization of a chimpanzee with a PND-binding monoclonal antibody prevented infection. ** In contrast, neutralization determinants on SIV have not been defined. Immunization with inactivated SIV confers protection against virus challenge (4-7), as does passive immunization of cynomolgus monkeys with high-titer immune sera (20) . Thus, although antibody appears to be sufficient to confer protective immunity to SIV, the nature of this antibody-mediated protective immune response is unknown. Further, the role played by neutralizing antibody in protective immunity to SIV has not been elucidated.
To investigate the ability of SIV envelope subunits to elicit virus-neutralizing antibody, we produced envelope proteins and recombinant and synthetic fragments thereof from SIVmac251. These were analyzed for the ability both to elicit neutralizing antibody and to absorb neutralizing antibody from sera of SIVmac25l-infected animals. Our results show that the PND of this SIV isolate resides in a 45-kDa fragment from the C-terminal half of the external glycoprotein and that it depends on the tertiary structure of the envelope protein and therefore cannot be mimicked by a synthetic peptide.
Simian immunodeficiency virus (SIV) causes an AIDS-like disease in several monkey species (for reviews see refs. [1] [2] [3] , and this virus is being used as a model for human immunodeficiency virus type 1 (HIV-1) pathogenesis, therapy, and vaccine development. Immunization with inactivated SIV confers protection from virus challenge (4) (5) (6) (7) . This has given encouragement that a vaccine can be developed to protect humans from HIV-1 infection.
Much of the research regarding HIV-1 vaccine development has focused on the external envelope glycoprotein gpl20. The principal neutralization determinant (PND) of HIV-1 is within a disulfide crossbridged loop in the third variable domain (the V3 loop) of gpl20 (8) (9) (10) (11) . Immunization with gpl20 (12) , gpl60 (13) , or PND-containing peptides (8-10, 14, 15) elicit virus-neutralizing antisera comparable in titer to sera from chimpanzees experimentally infected with HIV-1. Furthermore, serum fractionation has shown that PND peptides bind essentially all of the neutralizing antibodies elicited by gpl20 or gpl60 (8) Antisera. Each of the peptides was conjugated to keyhole limpet hemocyanin through a C-terminal cysteine (23) . Guinea pigs and goats were immunized as described (8, 15, 23) , with Freund's complete adjuvant (first immunization) and incomplete adjuvant (subsequent immunizations).
Neutralization Assays. For the syncytium reduction assay (24) , virus was diluted with growth medium to contain -100 syncytium-forming units per 30 ,l. Twofold serum dilutions (heat-inactivated, 56°C for 30 min) were made in half-area wells of 96-well plates. Virus (30 ,ul) was added to the wells and the cultures were incubated at 37°C for 30 min. HUT78 target cells (3 x 103 in 30 ,l) were then added and syncytia were enumerated 3-4 days later. The neutralization titer is expressed as the reciprocal of the serum dilution that inhibited syncytium formation by 90%o. The cell viability assay was done as described (4, 25 Fig. 2B ). In addition, we expressed in E. coli three fragments (Env7, Env2, and Env5) that collectively spanned nearly all of gpl40. Each of these proteins, except gpllO (denoted native gpllO), was purified using denaturing conditions. In contrast, gpllO was purified using nondenaturing conditions designed to maintain the native structure and hence the ability to bind CD4. Synthetic peptides were also synthesized that corresponded to several regions of SIVmac251 gpl40 (Fig. 2B) . Each of the proteins and selected keyhole limpet hemocyanin-conjugated peptides were used to elicit antisera in goats or guinea pigs.
These antisera and antisera taken from two SIVmac251-infected macaques were assessed by ELISA for binding to either the immunogen or gpl40 ( Table 1 ). The ability of these sera to neutralize the SIVmac25l isolate was assessed (i) by measuring the reduction in infectious virus by antiserum as assessed by the viability of virus-treated cell cultures (cell viability assay) (4, 25) and (ii) by measuring the antiserummediated reduction in the number of virus-induced syncytia (syncytium reduction assay) (24) . Sera from infected macaques neutralized the virus with titers of 45,000 and 800,000 in the syncytium reduction assay, and serum from one of the animals had a titer of 40,960 in the cell viability assay, indicating that sera from different animals can vary significantly in their ability to neutralize virus. Antisera to the peptides (including peptides RP92, -93, and -297, corresponding to the HIV-1 PND), the E. coli fragments Env7, -2, and -5, gp140, or native gpllO treated with reducing agents and urea (denoted denatured gpllO) did not neutralize the virus or did so with titers >100 times lower than SIVmac251-infected macaque sera. In contrast, antisera to native gpllO neutralized the virus with titers comparable to infected macaque sera.
Native gpllO Absorbs Essentially All Neutralizing Antibody from SIV-Infected Macaque Serum. These findings were confirmed and extended by assessing the ability of these proteins or peptides to inhibit neutralizing antibody in serum from an infected macaque or from a guinea pig immunized with native gpllO (Table 2) . Protein or peptides, at the indicated concentrations, were mixed with serum and the neutralization titer (syncytium reduction assay) was determined. Native gpllO, at a concentration that has no effect on virus infectivity, reduced the neutralizing titer of anti-gpllO serum by over 98% and of infected macaque serum by 99.8%. This indicates that essentially all of the neutralizing antibodies elicited by either native gpllO or infectious virus bind 702 nonapeptides, each staggered by one amino acid over the length of gpl40. Reactivity of antibodies in the two sera with each peptide was determined (Fig. 2C) . Both sera reacted with few determinants, all of which were within gpllO, and there were only two regions (surrounding amino acids 150 and 490, which are within Env7 and Env5, respectively) that reacted with antibodies in both sera. The peptides corresponding to the HIV-1 PND reacted with the infected macaque serum but not with the gpllO antiserum. The fact that peptides corresponding to this region did not elicit or absorb neutralizing antibody from either of these sera shows that this determinant, at least as a peptide independent of other determinants on the envelope, is not a neutralization determinant. This was true even when this peptide was synthesized (RP297) ( Table 2) in its entirety with an intramolecular disulfide crossbridge to attempt to mimic this domain as it exists in HIV gpl20 and that is proposed to exist in SIV and HIV-2 gp120 (26) .
The PND Resides in a 45-kDa Fragment. To localize the binding site of neutralizing antibodies on gpllO, native gpllO was treated either with N-Glycanase, which hydrolyzes N-linked oligosaccharides, or with V8 protease. N-Glycanase reduced the apparent size of gpllO to 70 kDa (Fig. 1,  lane 4) . This 70-kDa protein reduced the neutralization titer of anti-gpllO serum or infected macaque serum by about 87% and 98%, respectively (Table 2 ). This indicates that gpllO deglycosylated in this manner is recognized by neutralizing antibodies, although less efficiently than is native gpllO, but that the majority of the neutralizing antibodies bind to deglycosylated gpllO. It is possible that removal of carbohydrate alters the tertiary structure of native gpllO, thereby making it less efficiently recognized by neutralizing antibody.
Treatment of native gpllO with V8 protease, under conditions designed to maintain the native structure of the digestion products, resulted in fragments of45, 25 and 20 kDa visible by Coomassie blue staining after nonreducing SDS/ PAGE (Fig. 1, lane 6) . The V8 digestion products reduced the neutralization titer of both the anti-gpllO and infected macaque sera comparably to native gpllO. Native gel electrophoresis, followed by Western blotting and probing with either of these antisera, revealed that primarily the 45-kDa fragment was immunoreactive (data not shown), suggesting that it contains the PND(s). The 45-kDa fragment was therefore purified by gel filtration chromatography (Fig. 1, lane 5) . Amino acid sequencing showed the N terminus to be at amino acid 249 (Fig. 2) . Based on the apparent molecular mass, and assuming that the mass contributed by the carbohydrate is equally distributed over the length of gpllO, we estimate that the C terminus of the 45 kDa fragment is near amino acid 460. 5-9 ) or with OKT4A (lane 3), and the antibody and sCD4 were precipitated with protein A-Sepharose. The precipitate was electrophoresed, transferred to nitrocellulose and probed with antisera to both gpllO and CD4. If envelope proteins bound sCD4 and were hence coprecipitated, they appear as a band in addition to that of sCD4. Lanes 1 and 4, gpll0 and sCD4 proteins directly electrophoresed without immunoprecipitation; lanes 2 and 5, gpll0 and sCD4 precipitated with OKT4; lane 3, gpl10, sCD4, and OKT4A; lane 6, gpllO (treated under deglycosylation conditions without N-Glycanase), sCD4, and OKT4; lane 7, denatured gpllO, sCD4, and OKT4; lane 8, 45-kDa fragment, sCD4, and OKT4; lane 9, deglycosylated gp110, sCD4, and OKT4.
The 45-kDa fragment, therefore, contains the six C-terminal cysteines in gpllO and encompasses the analogous HIV-1 PND and CD4-binding domain.
The purified 45-kDa fragment reduced the neutralization titer of anti-gpllO serum and infected macaque serum by 15-and 55-fold, respectively, indicating that the large majority of neutralizing antibodies in these sera bind to the 45-kDa fragment. Consistent with our previous results, when the 45-kDa fragment was denatured, it no longer reduced the neutralization titer of either sera. This shows that the PND is contained in this fragment and that the ability to bind neutralizing antibody depends on its tertiary structure.
Native gpllO, But Not Denatured gpllO, Binds CD4. To determine whether native gpllO has the tertiary structure to allow it to bind to CD4, we tested whether it could prevent virus infection in the syncytium reduction assay and whether it bound CD4 in an immunoprecipitation assay. Native gpllO prevented syncytium formation (IC50 0.2 ,uM; data not shown), suggesting that it can bind CD4 and prevent virus attachment. In contrast, denatured gpllO, gpl40, deglycosylated gpllO, and the 45-kDa fragment, even at 0.5 ,uM, did not reduce the number of syncytium. This suggests that these proteins do not bind CD4. The CD4-binding ability of these proteins was tested directly in an immunoprecipitation assay in which the protein was incubated with human sCD4, the sCD4 was precipitated with OKT4 antibody and protein A-Sepharose, and the precipitate was analyzed by gel electrophoresis and Western blotting for both sCD4 and the envelope protein. Whereas native gpllO was precipitated by virtue of its ability to bind sCD4 (Fig. 3, lanes 2, 5, and 6 ), the denatured (lane 7) or deglycosylated (lane 9) gpllO and the 45-kDa fragment (lane 8) were not. gpllO was not precipitated by sCD4 and OKT4A (lane 3). These results parallel those obtained with HIV-1 gpl20, which when denatured or fragmented shows a large reduction in the ability to bind CD4 (29) (30) (31) (32) (33) .
DISCUSSION
The data show that the PND of HIV-1 differs from that of SIVmac251. In contrast to HIV-1, the native form of SIVmtac251 gpllO is necessary to elicit appreciable titers of neutralizing antibody, and denatured gpllO, gpl40, large envelope fragments, or synthetic peptides containing the region corre-sponding to the HIV-1 PND do not elicit or absorb measurable amounts of neutralizing antibody. Therefore, the integrity of the PND of this SIV isolate depends on the tertiary structure of gpllO. Whereas the sequence of the PND of HIV-1 varies significantly among different HIV-1 isolates (11), the corresponding region in the SIV, envelope is less variable-among SIVmac isolates from different infected animals (34) and among isolates taken from a single infected animal (35) . This suggests that immunological selective pressure, such as neutralizing antibody, is not placed on this envelope sequence during infection.
Although we have not determined precisely the determinant(s) to which the SIV-neutralizing antibodies bind, because its integrity depends on the native tertiary structure of gpllO, the determinant probably consists of amino acids adjacent in the tertiary structure but distant in the primary sequence. Polio-, rhino-, and foot-and-mouth-disease viruses, for example, contain such major nonlinear neutralization determinants (36) (37) (38) . In addition to the PND, HIV-1 elicits neutralizing antibodies that bind to other determinants (16, (39) (40) (41) (42) . For example, fractionation of neutralizing antisera from selected HIV-1-infected humans with PND peptides indicates that a significant fraction of neutralizing antibodies in such sera do not bind the PND (16) . Furthermore, monoclonal antibodies (39, 40, 42) that block binding of gpl2O to CD4, derived from HIV-1-infected individuals, bind to native but not to denatured gpl20 and thus recognize a determinant dependent on the tertiary structure.
Immunization with inactivated SIV confers protection against virus challenge (4-7). It remains to be determined whether native gpllO induces neutralizing antibody that will confer protection from SIV challenge. Whether the properties of the neutralizing determinants of other SIV isolates will be similar to those reported here and how useful SIV will be for assisting the development of a vaccine for HIV-1 remain to be determined.
